FierceBiotech 15. Apr. 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech 27. März 2026 Novartis pens $2B deal for allergy biotech with potential Xolair successor
FierceBiotech 23. März 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech 20. März 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
FierceBiotech 27. Feb. 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech 18. Feb. 2026 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
FierceBiotech 4. Feb. 2026 Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
FierceBiotech 9. Dez. 2025 Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech